FOLH1 and prostate carcinoma: Primary endpoint was partial response (PR), defined as either a decline in prostate specific antigen of ≥ 50% (according to prostate cancer clinical trial working group) or PET-based response according to Response Evaluation Criteria on PSMA PET/CT.